Suzanne Hollander, MS, RD, LDN; and Timothy Tramontana, MD, offer thoughts on newly FDA-approved sepiapterin for PKU.
Suzanne Hollander, MS, RD, LDN
Advertisement
Suzanne Hollander, MS, RD, LDN, Senior Clinical Nutrition Specialist, Boston Children's Hospital.
Articles by Suzanne Hollander, MS, RD, LDN
In this interview, Suzanne Hollander, MS, RD, LDN, discusses the importance of collaborative care in PKU and the impact of a new potential treatment.
A review of the clinical potential of PTC Therapeutics' sepiapterin as a novel treatment for phenylketonuria (PKU).
Advertisement
Latest Updated Articles
PKU and the pediatrician with Suzanne Hollander, MS, RD, LDNPublished: May 8th 2025 | Updated:
PKU and sepiapterin data with Suzanne Hollander, MS, RD, LDNPublished: May 7th 2025 | Updated:
WATCH: Experts react to the FDA approval of sepiapterin to treat PKUPublished: July 29th 2025 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Safety, tolerability of tenapanor in pediatric IBS-C patients, with Thomas Wallach, MD
2
Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C
3
Odevixibat demonstrates sustained pruritus and bile acid improvements in FIC1 deficiency
4
Linaclotide demonstrates positive long-term safety
5
